Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non Operating Income (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Non Operating Income for 10 consecutive years, with -$473000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 116.81% to -$473000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.6 million through Dec 2025, down 176.41% year-over-year, with the annual reading at -$4.0 million for FY2025, 176.73% down from the prior year.
  • Non Operating Income for Q4 2025 was -$473000.0 at Rhythm Pharmaceuticals, down from $274000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $100.2 million in Q1 2021, with the low at -$2.4 million in Q1 2025.
  • Average Non Operating Income over 5 years is $4.9 million, with a median of $116500.0 recorded in 2021.
  • The sharpest move saw Non Operating Income soared 8716.37% in 2021, then tumbled 1255.07% in 2022.
  • Over 5 years, Non Operating Income stood at $447000.0 in 2021, then crashed by 456.15% to -$1.6 million in 2022, then surged by 85.87% to -$225000.0 in 2023, then soared by 1350.22% to $2.8 million in 2024, then tumbled by 116.81% to -$473000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$473000.0, $274000.0, and -$999000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.